A new EU-funded project is exploring the use of nanoparticles in the diagnosis and treatment of Alzheimer's disease. The five-year NAD ('Nanoparticles for the therapy and diagnosis of Alzheimer's disease') initiative has a budget of €14.6 million and is financed by the EU's Seventh Framework Programme (FP7). It brings together researchers from a variety of disciplines working in 19 organisations in 13 countries.
Alzheimer's disease is the most common form of dementia: of Europe's five million dementia sufferers, over half have a diagnosis of Alzheimer's. These figures are likely to rise dramatically as the population ages. The condition is caused by the accumulation in the brain of plaques made up of beta-amyloid peptide molecules. These plaques cause the nerve cells to degenerate.
Symptoms of Alzheimer's include confusion, memory loss and mood swings. As yet, there is no cure for the condition, although some drugs exist that are able to slow the progression of the disease in some patients.
'Somewhere in the world there is a new case of dementia diagnosed every seven seconds. The majority of these people are suffering from Alzheimer's disease,' said Professor David Allsop of Lancaster University in the UK, one of the project partners. 'But despite great progress in the scientific field, which has made interpretation of the molecular bases of the disease possible, so far there has been little progress in improved diagnosis and therapy.'
The NAD project will design a range of nanoparticles that are...Read the whole article